Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1996 Feb 1;154(3):363–368.

The use of oral ganciclovir in the treatment of cytomegalovirus retinitis in patients with AIDS.

C Ward-Able 1, P Phillips 1, C M Tsoukas 1
PMCID: PMC1487517  PMID: 8564906

Abstract

OBJECTIVE: To recommend the appropriate use of oral ganciclovir as an alternative to intravenous (i.v.) maintenance therapy for cytomegalovirus (CMV) retinitis in patients with AIDS. OPTIONS: i.v. infusion of ganciclovir and foscarnet have been the only approved choices for maintenance therapy until the introduction of oral ganciclovir. OUTCOMES: Ease of administering maintenance therapy and improved quality of life for patients with AIDS. VALUES: The medical advisory group comprised physicians treating patients with AIDS therapy. Ease of administration of maintenance therapy and quality of patients' lives were considered important. BENEFITS, HARMS AND COSTS: Oral ganciclovir is a safe and convenient alternative to i.v. maintenance therapy for patients with CMV retinitis. However, its low bio-availability precludes its use for induction therapy and necessitates careful monitoring for compliance. Compared with i.v. administration of ganciclovir, oral maintenance therapy is cost effective. EVIDENCE: Evidence for the guidelines was gathered from data presented at a symposium on CMV retinitis and oral ganciclovir, clinical trials of oral ganciclovir and input from a visiting expert. It was presented at a meeting of the advisory board whose members are involved in the care of patients with AIDS and the management of CMV retinitis. The guidelines were approved by each member of the advisory board. RECOMMENDATIONS: Diagnosis, treatment and follow-up of CMV retinitis should always be in consultation with an ophthalmologist who is experienced in treating this disease. The patient should be fully informed about the limitations of the oral form of ganciclovir; he or she should be involved in decision making and carefully monitored. Oral ganciclovir should not be used for induction therapy or for maintenance therapy in high-risk patients. VALIDATION: Similar guidelines have been produced in England where the drug has been available since January 1995. SPONSOR: The deliberations of the advisory board and the preparation of this report were funded through an educational grant from Hoffmann-La Roche (Canada).

Full text

PDF
363

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Drew W. L. Cytomegalovirus infection in patients with AIDS. Clin Infect Dis. 1992 Feb;14(2):608–615. doi: 10.1093/clinids/14.2.608-a. [DOI] [PubMed] [Google Scholar]
  2. Drew W. L., Ives D., Lalezari J. P., Crumpacker C., Follansbee S. E., Spector S. A., Benson C. A., Friedberg D. N., Hubbard L., Stempien M. J. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N Engl J Med. 1995 Sep 7;333(10):615–620. doi: 10.1056/NEJM199509073331002. [DOI] [PubMed] [Google Scholar]
  3. Holland G. N., Pepose J. S., Pettit T. H., Gottlieb M. S., Yee R. D., Foos R. Y. Acquired immune deficiency syndrome. Ocular manifestations. Ophthalmology. 1983 Aug;90(8):859–873. doi: 10.1016/s0161-6420(83)80009-8. [DOI] [PubMed] [Google Scholar]
  4. Holland G. N., Sidikaro Y., Kreiger A. E., Hardy D., Sakamoto M. J., Frenkel L. M., Winston D. J., Gottlieb M. S., Bryson Y. J., Champlin R. E. Treatment of cytomegalovirus retinopathy with ganciclovir. Ophthalmology. 1987 Jul;94(7):815–823. doi: 10.1016/s0161-6420(87)33534-1. [DOI] [PubMed] [Google Scholar]
  5. Jabs D. A., Enger C., Bartlett J. G. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol. 1989 Jan;107(1):75–80. doi: 10.1001/archopht.1989.01070010077031. [DOI] [PubMed] [Google Scholar]
  6. Jabs D. A., Green W. R., Fox R., Polk B. F., Bartlett J. G. Ocular manifestations of acquired immune deficiency syndrome. Ophthalmology. 1989 Jul;96(7):1092–1099. doi: 10.1016/s0161-6420(89)32794-1. [DOI] [PubMed] [Google Scholar]
  7. Jabs D. A., Newman C., De Bustros S., Polk B. F. Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology. 1987 Jul;94(7):824–830. doi: 10.1016/s0161-6420(87)33535-3. [DOI] [PubMed] [Google Scholar]
  8. Jacobson M. A., O'Donnell J. J., Brodie H. R., Wofsy C., Mills J. Randomized prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitis. J Med Virol. 1988 Jul;25(3):339–349. doi: 10.1002/jmv.1890250311. [DOI] [PubMed] [Google Scholar]
  9. Jacobson M. A., O'Donnell J. J., Mills J. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrob Agents Chemother. 1989 May;33(5):736–741. doi: 10.1128/aac.33.5.736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Katlama C. Cytomegalovirus infection in acquired immune-deficiency syndrome. J Med Virol. 1993;Suppl 1:128–133. doi: 10.1002/jmv.1890410525. [DOI] [PubMed] [Google Scholar]
  11. Laskin O. L., Cederberg D. M., Mills J., Eron L. J., Mildvan D., Spector S. A. Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. Am J Med. 1987 Aug;83(2):201–207. doi: 10.1016/0002-9343(87)90685-1. [DOI] [PubMed] [Google Scholar]
  12. Palestine A. G., Polis M. A., De Smet M. D., Baird B. F., Falloon J., Kovacs J. A., Davey R. T., Zurlo J. J., Zunich K. M., Davis M. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med. 1991 Nov 1;115(9):665–673. doi: 10.7326/0003-4819-115-9-665. [DOI] [PubMed] [Google Scholar]
  13. Palestine A. G., Rodrigues M. M., Macher A. M., Chan C. C., Lane H. C., Fauci A. S., Masur H., Longo D., Reichert C. M., Steis R. Ophthalmic involvement in acquired immunodeficiency syndrome. Ophthalmology. 1984 Sep;91(9):1092–1099. doi: 10.1016/s0161-6420(84)34201-4. [DOI] [PubMed] [Google Scholar]
  14. Pepose J. S., Holland G. N., Nestor M. S., Cochran A. J., Foos R. Y. Acquired immune deficiency syndrome. Pathogenic mechanisms of ocular disease. Ophthalmology. 1985 Apr;92(4):472–484. doi: 10.1016/s0161-6420(85)34008-3. [DOI] [PubMed] [Google Scholar]
  15. Spector S. A., Busch D. F., Follansbee S., Squires K., Lalezari J. P., Jacobson M. A., Connor J. D., Jung D., Shadman A., Mastre B. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group. J Infect Dis. 1995 Jun;171(6):1431–1437. doi: 10.1093/infdis/171.6.1431. [DOI] [PubMed] [Google Scholar]
  16. Spector S. A., Weingeist T., Pollard R. B., Dieterich D. T., Samo T., Benson C. A., Busch D. F., Freeman W. R., Montague P., Kaplan H. J. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group. J Infect Dis. 1993 Sep;168(3):557–563. doi: 10.1093/infdis/168.3.557. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES